Inventor

Lucien Maria Henricus Koymans

Inventor

Retie, BE

Overview

2000–2020

Patent span

Human necessities

Primary field (CPC A)

Patents· 33 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

A61Pprimary

A61PSpecific therapeutic activity of chemical compounds or medicinal preparations31%

C07DHeterocyclic compounds29%

A61KPreparations for medical, dental or toiletry purposes22%

B82YSpecific uses or applications of nanostructures6%

C07CAcyclic or carbocyclic compounds6%

C07KPeptides2%

C12NMicroorganisms or enzymes2%

G01NInvestigating or analysing materials by determining their chemical or physical properties2%

Y10STechnical subjects covered by former uspc cross-reference art collections [xracs] and digests2%

PatentTitleYear

10,611,732HIV replication inhibiting pyrimidines2020 10,370,340HIV replication inhibiting pyrimidines2019 9,981,919HIV replication inhibiting pyrimidines2018 9,580,392'HIV replication inhibiting pyrimidines'2017 8,828,982'Pyrimidine derivatives for the prevention of HIV infection'2014 8,530,655'HIV replication inhibiting pyrimidines'2013 8,378,085'Bacterial ATP synthase binding domain'2013 8,088,891'Bacterial ATP synthase binding domain'2012 8,080,551'HIV inhibiting pyrimidines derivatives'2011 8,026,245'HIV replication inhibiting purine derivatives'2011 8,026,248'HIV inhibiting pyrimidine derivatives'2011 8,003,789'HIV replication inhibiting pyrimidines'2011 7,923,554'HIV inhibiting 1,2,4-triazin-6-one derivatives'2011 7,763,631'Prodrugs of HIV replication inhibiting pyrimidines'2010 7,585,861'HIV inhibiting 1,2,4-triazines'2009 7,585,870'HIV replication inhibiting pyrimidines and triazines'2009 7,514,445'Heteroaryl amines as glycogen synthase kinase 3Î² inhibitors (GSK3 inhibitors)'2009 7,442,705'HIV replication inhibiting pyrimidines and triazines'2008 7,276,510'HIV replication inhibitors'2007 7,183,288'Amide derivatives as glycogen synthase kinase 3-Î² inhibitors'2007 7,125,879'HIV inhibiting pyrimidines derivatives'2006 7,105,522'HIV inhibiting pyrazinone derivatives'2006 7,037,917'HIV replication inhibiting pyrimidines'2006 7,034,019'Prodrugs of HIV replication inhibiting pyrimidines'2006 7,015,221'2,4-disubstituted triazine derivatives'2006 6,903,213'HIV inhibiting pyrimidine derivatives'2005 6,878,717'HIV replication inhibiting pyrimidines'2005 6,774,235'Trisubstituted 1,3,5-triazine derivatives'2004 6,638,932'2,4-disubstituted triazine derivatives'2003 6,440,986'HIV Inhibiting pyrimidine derivatives'2002 6,372,729'Trisubstituted 1,3,5,-triazine derivatives'2002 6,197,779'HIV inhibiting pyrimidine derivative'2001 6,150,360'Trisubstituted 1,3,5-Triazine Derivatives'2000

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

2000–2020Patents assigned to JANSSEN PHARMACEUTICA NV (26)· patent assignee history

2000–2011Based in Turnhout, BE· patent location history

2003–2020Based in Retie, BE· patent location history

2007–2014Patents assigned to KOYMANS LUCIEN MARIA HENRICUS (6)· patent assignee history

2007–2013Patents assigned to DE JONGE MARC RENE (4)· patent assignee history

2007–2014Patents assigned to HEERES JAN (4)· patent assignee history

2007Based in Beerse, BE· patent location history

2012–2013Patents assigned to ANDRIES KOENRAAD JOZEF LODEWIJK MARCEL (3)· patent assignee history

Inventor activity

Assignee and location history derived from the patent record.

Assignees

Assignee	Patents	Span
JANSSEN PHARMACEUTICA NV	26	2000–2020
KOYMANS LUCIEN MARIA HENRICUSself	6	2007–2014
DE JONGE MARC RENE	4	2007–2013
HEERES JAN	4	2007–2014
ANDRIES KOENRAAD JOZEF LODEWIJK MARCEL	3	2012–2013

Locations

Location	Patents	Span
Retie, BE	23	2003–2020
Turnhout, BE	9	2000–2011
Beerse, BE	1	2007